Department of Medical Oncology, European Hospital Georges Pompidou & University of Paris, 20 rue Leblanc, Paris, 75015, France.
Future Oncol. 2021 Jan;17(1):91-102. doi: 10.2217/fon-2020-0672. Epub 2020 Dec 2.
Cabazitaxel (25 mg/m every 3 weeks) is the standard second-line chemotherapy for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. It is associated with a risk of neutropenic complications, which may be a barrier to its use in daily clinical practice, particularly in frail elderly patients. Here the authors reviewed key studies conducted with cabazitaxel (TROPIC, PROSELICA, AFFINITY, CARD and the European compassionate use program) and pilot studies with adapted schedules. Based on this review, the use of prophylactic granulocyte colony-stimulating factor from cycle 1 appears crucial to maximize the benefit-risk ratio of cabazitaxel in metastatic castration-resistant prostate cancer. Preliminary data with alternative schedules look promising, especially for frail patients. Results of the ongoing Phase III CABASTY trial (ClinicalTrials.gov: NCT02961257) are awaited.
卡巴他赛（25mg/m，每 3 周）是既往接受多西他赛治疗的转移性去势抵抗性前列腺癌患者的标准二线化疗药物。其与中性粒细胞减少并发症风险相关，这可能成为其在日常临床实践中应用的障碍，尤其是在体弱的老年患者中。作者在此回顾了卡巴他赛的关键研究（TROPIC、PROSELICA、AFFINITY、CARD 及欧洲同情用药计划）和适应方案的试点研究。基于此回顾，第 1 周期应用粒细胞集落刺激因子预防似乎对最大化转移性去势抵抗性前列腺癌患者的卡巴他赛获益风险比至关重要。替代方案的初步数据很有前景，尤其是对体弱患者。目前正在进行的 III 期 CABASTY 试验（ClinicalTrials.gov：NCT02961257）的结果正在等待中。
